IDL’s Q3 report missed our forecast on sales, owing to fluctuations in APAC for TUBEX. Still, it continued to demonstrate good cost control and is moving into a Q4 that should see a sales rebound. We reiterate our SEK1.0 base case.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/
Attachments
IDL Diagnostics (Q3 Review) - Temporary headwinds in APAC
© Modular Finance, source Nordic Press Releases